The price and value of therapeutic synergy in liver cancer
暂无分享,去创建一个
[1] A. Gasbarrini,et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study , 2023, The Lancet.
[2] B. Vincenzi,et al. Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. , 2023, JHEP reports : innovation in hepatology.
[3] D. Pinato,et al. NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] M. Kudo,et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. , 2022, European journal of cancer.
[5] P. Galle,et al. LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) , 2022, Annals of Oncology.
[6] G. Cabibbo,et al. Hepatitis B Virus-Associated Hepatocellular Carcinoma , 2022, Viruses.
[7] M. Kudo,et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. , 2022, Journal of Clinical Oncology.
[8] M. Kudo,et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. , 2021, The Lancet. Oncology.
[9] J. Bruix,et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.
[10] C. Porta,et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.
[11] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[12] Hashem B. El-Serag,et al. Epidemiology of Hepatocellular Carcinoma , 2020, Hepatology.
[13] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[14] M. Zoli,et al. Prognosis of untreated hepatocellular carcinoma , 2015, Hepatology.